An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma

Merel van Nuland; Hilde Rosing; Jelle de Vries; Huib Ovaa; Jan H M Schellens; Jos H Beijnen

doi:10.1016/j.jchromb.2017.10.033

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma

Merel van Nuland
, Hilde Rosing
, Jelle de Vries
, Huib Ovaa
, Jan H M Schellens
, Jos H Beijnen

Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands; Division of pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: [email protected].
Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.
Division of Cell Biology II, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Department of Chemical Immunology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands. Electronic address: [email protected].

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Δ(4)-Abiraterone (D4A) is a recently discovered active metabolite of the oral anti-androgen drug abiraterone acetate. For quantification of this metabolite in human plasma, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated. Human plasma samples of patients treated with abiraterone acetate were prepared by protein precipitation with acetonitrile. The method was validated over a linear range of 0.2-20ng/mL. Intra-assay and inter-assay variabilities were within ±15% of the nominal concentrations for quality control (QC) samples at medium and high concentrations and within ±20% at the lower limit of quantification (LLOQ), respectively. The described method for quantification of D4A was validated successfully and implemented to support therapeutic drug monitoring in patients treated with abiraterone acetate.

Original language	English
Pages (from-to)	119-124
Number of pages	6
Journal	Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume	1068-1069
DOIs	https://doi.org/10.1016/j.jchromb.2017.10.033
Publication status	Published - 15 Nov 2017

Keywords

Androstenes
Chromatography, Liquid
Drug Monitoring
Humans
Linear Models
Reproducibility of Results
Sensitivity and Specificity
Tandem Mass Spectrometry

Access to Document

10.1016/j.jchromb.2017.10.033

nulandFinal published version, 462 KBLicence: Taverne

Cite this

@article{d5cb1bc6bb5845e9ab29729ebaad53ee,

title = "An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma",

abstract = "Δ(4)-Abiraterone (D4A) is a recently discovered active metabolite of the oral anti-androgen drug abiraterone acetate. For quantification of this metabolite in human plasma, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated. Human plasma samples of patients treated with abiraterone acetate were prepared by protein precipitation with acetonitrile. The method was validated over a linear range of 0.2-20ng/mL. Intra-assay and inter-assay variabilities were within ±15\% of the nominal concentrations for quality control (QC) samples at medium and high concentrations and within ±20\% at the lower limit of quantification (LLOQ), respectively. The described method for quantification of D4A was validated successfully and implemented to support therapeutic drug monitoring in patients treated with abiraterone acetate.",

keywords = "Androstenes, Chromatography, Liquid, Drug Monitoring, Humans, Linear Models, Reproducibility of Results, Sensitivity and Specificity, Tandem Mass Spectrometry",

author = "\{van Nuland\}, Merel and Hilde Rosing and \{de Vries\}, Jelle and Huib Ovaa and Schellens, \{Jan H M\} and Beijnen, \{Jos H\}",

year = "2017",

month = nov,

day = "15",

doi = "10.1016/j.jchromb.2017.10.033",

language = "English",

volume = "1068-1069",

pages = "119--124",

journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",

issn = "1570-0232",

publisher = "Elsevier BV",

}

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma. / van Nuland, Merel; Rosing, Hilde; de Vries, Jelle et al.
In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 1068-1069, 15.11.2017, p. 119-124.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma

AU - van Nuland, Merel

AU - Rosing, Hilde

AU - de Vries, Jelle

AU - Ovaa, Huib

AU - Schellens, Jan H M

AU - Beijnen, Jos H

PY - 2017/11/15

Y1 - 2017/11/15

N2 - Δ(4)-Abiraterone (D4A) is a recently discovered active metabolite of the oral anti-androgen drug abiraterone acetate. For quantification of this metabolite in human plasma, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated. Human plasma samples of patients treated with abiraterone acetate were prepared by protein precipitation with acetonitrile. The method was validated over a linear range of 0.2-20ng/mL. Intra-assay and inter-assay variabilities were within ±15% of the nominal concentrations for quality control (QC) samples at medium and high concentrations and within ±20% at the lower limit of quantification (LLOQ), respectively. The described method for quantification of D4A was validated successfully and implemented to support therapeutic drug monitoring in patients treated with abiraterone acetate.

AB - Δ(4)-Abiraterone (D4A) is a recently discovered active metabolite of the oral anti-androgen drug abiraterone acetate. For quantification of this metabolite in human plasma, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated. Human plasma samples of patients treated with abiraterone acetate were prepared by protein precipitation with acetonitrile. The method was validated over a linear range of 0.2-20ng/mL. Intra-assay and inter-assay variabilities were within ±15% of the nominal concentrations for quality control (QC) samples at medium and high concentrations and within ±20% at the lower limit of quantification (LLOQ), respectively. The described method for quantification of D4A was validated successfully and implemented to support therapeutic drug monitoring in patients treated with abiraterone acetate.

KW - Androstenes

KW - Chromatography, Liquid

KW - Drug Monitoring

KW - Humans

KW - Linear Models

KW - Reproducibility of Results

KW - Sensitivity and Specificity

KW - Tandem Mass Spectrometry

U2 - 10.1016/j.jchromb.2017.10.033

DO - 10.1016/j.jchromb.2017.10.033

M3 - Article

C2 - 29059586

SN - 1570-0232

VL - 1068-1069

SP - 119

EP - 124

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

ER -

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma

Abstract

Keywords

Access to Document

Fingerprint

Cite this